Crossmark

Comparisons of choroidal thickness and volume in eyes with central serous chorioretinopathy to that of control eyes determined by ultra-widefield optical coherence tomography

Crossref DOI link: https://doi.org/10.1007/s00417-024-06409-w

Published Online: 2024-02-27

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maruko, Ichiro https://orcid.org/0000-0001-5647-6372
Maruko, Ruka

Kawano, Taizo

Iida, Tomohiro
License Information

Text and Data Mining valid from 2024-02-27

Version of Record valid from 2024-02-27
More Information

Article History

Received: 31 August 2023

Revised: 20 January 2024

Accepted: 2 February 2024

First Online: 27 February 2024

Declarations

:

: The procedures used conformed to the tenets of the Declaration of Helsinki and were approved by the Institutional Review Board of the Tokyo Women’s Medical University.

: Maruko I. received grants from JSPS KAKENHI (grant number JP 20K09781) and lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, and Nikon. He holds a patent.Maruko R. received lecturing and travel fees from Kyowa Kirin.Kawano T. has no conflict of interest.Iida T. received grants from Nidek, Topcon, Santen, Novartis Pharma, Senju Pharmaceutical, Japan Alcon, HOYA, and AMO; consultant fees from Bayer Pharmaceuticals, Novartis Pharma, Chugai Pharmaceutical, Japan Beringer Ingelheim, and Janssen Pharma; and received lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, Otsuka Pharmaceutical, Nikon, and Kyowa Kirin. He holds a patent.

Document is current

Any future updates will be listed below